CFO & Treasurer Of Castle Biosciences Sold 41% Of Their Shares
Castle Biosciences' CFO & Treasurer, Frank Stokes, recently sold US$742k worth of stock, reducing his holding by 41%. This was the largest insider sale in the past year, and while it's generally seen as a negative signal, it doesn't definitively indicate that insiders believe the shares are overvalued. Insiders currently own 2.4% of the company's shares.
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. announced its participation in two upcoming investor conferences in September 2026. The company's executive management will present at Baird's 2026 Global Healthcare Conference on September 15, 2026, and will be available for one-on-one meetings at the 10th annual Lake Street Best Ideas Growth (BIG10) Conference on September 10, 2026. Castle Biosciences is a diagnostics company focused on improving health through innovative tests in dermatologic and gastroenterological disease.
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Analysts
Castle Biosciences, Inc. (NASDAQ:CSTL) has received a "Moderate Buy" rating from analysts, with an average 12-month price target of $42.00, significantly above its recent opening price. The company exceeded quarterly revenue and adjusted EPS expectations but remains unprofitable with a negative net margin. Institutional ownership is high at 92.6%, though insiders have recently sold shares under pre-arranged trading plans.
Castle Biosciences CCO Tobin W Juvenal Sells 1,730 Shares via 10b5-1 Trading Plan
Castle Biosciences Inc. Chief Commercial Officer Tobin W Juvenal sold 1,730 shares of company common stock on August 17, 2026, under a pre-established Rule 10b5-1 trading plan. The shares were sold at a weighted-average price of $29.59, with individual transactions ranging from $29.21 to $30.01. Following this sale, Juvenal directly holds 75,964 shares of common stock in Castle Biosciences.
Castle Biosciences CFO Frank Stokes Sells 24,908 Shares in Open Market Transaction
Frank Stokes, CFO of Castle Biosciences Inc. (NASDAQ:CSTL), sold 24,908 shares of company stock in an open market transaction on August 14, 2026. The shares were sold at a weighted-average price of $29.77, with individual trades ranging from $29.71 to $29.97. Following this sale, Stokes retains direct beneficial ownership of 35,177 shares of Castle Biosciences common stock.
Castle Biosciences (CSTL) CFO sells 24,908 company shares
Castle Biosciences (CSTL) Chief Financial Officer, Frank Stokes, sold 24,908 shares of common stock on August 14, 2026, at a weighted-average price of $29.77 per share. The transaction, executed in multiple trades between $29.71 and $29.97, resulted in Stokes directly holding 35,177 shares after the sale. This insider trading activity was reported in a Form 4 filing with the SEC, indicating a "Very High" filing impact and "Negative" sentiment.
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
Castle Biosciences (Nasdaq: CSTL) has been approved for a dual listing on Nasdaq Texas, a new exchange headquartered in Dallas, while maintaining its primary listing on The Nasdaq Global Market. This move reflects the company's strong ties to Texas and its commitment to supporting the state's growth as a hub for life sciences innovation. The dual listing aims to increase the company's visibility among investors without affecting its operations, reporting obligations, or capital structure.
Castle Biosciences gains dual listing on Nasdaq Texas
Castle Biosciences Inc. (NASDAQ:CSTL) has secured a dual listing for its common stock on Nasdaq Texas, a new exchange based in Dallas. While maintaining its primary listing on The Nasdaq Global Market, the diagnostics company, which originated in Texas, will also trade on Nasdaq Texas under the same ticker symbol. This move highlights Castle Biosciences' connection to Texas and provides an additional avenue for investor engagement without impacting its operations or capital structure.
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
Castle Biosciences, Inc. (Nasdaq: CSTL) has been approved for a dual listing on Nasdaq Texas, a new exchange headquartered in Dallas, while maintaining its primary listing on The Nasdaq Global Market. The company, which is based in Texas, believes this move reflects its roots and commitment to the state's growth as a life sciences innovation hub. The dual listing is expected to increase investor visibility and support Texas's role as a center for business and innovation, without affecting investors' ability to buy or sell the stock, business operations, or capital structure.
AIGH Capital Management LLC Buys Shares of 545,101 Castle Biosciences, Inc. $CSTL
AIGH Capital Management LLC has acquired 545,101 shares of Castle Biosciences, Inc. (NASDAQ:CSTL) for approximately $13 million, making it their 20th-largest portfolio holding. Castle Biosciences recently surpassed quarterly earnings and revenue estimates. Despite significant insider selling over the past 90 days, analysts maintain a "Moderate Buy" consensus with an average price target of $42.
Quantinno Capital Management LP Purchases 36,144 Shares of Castle Biosciences, Inc. $CSTL
Quantinno Capital Management LP significantly increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 387.3% in the first quarter, acquiring an additional 36,144 shares. This brings their total holdings to 45,476 shares, valued at approximately $1.12 million. While institutional investors own a large portion of the stock, company insiders have recently sold shares, including a COO and another insider under Rule 10b5-1 plans. Analysts maintain a "Moderate Buy" rating for CSTL with a consensus target price of $42.00, following the company's recent beat on quarterly revenue and EPS estimates.
CSTL (CSTL) insider and family trusts detail planned and recent stock sales
A recent SEC Form 144 filing indicates a planned sale of 25,792 shares of CSTL common stock, valued at $763,959.04, by an insider and related family trusts, to be executed around August 14, 2026, through Goldman Sachs & Co. LLC. The filing also details numerous past sales by Derek Maetzold and various family trusts between May and August 2026, including shares acquired through cashless exercise of stock options. Key figures include 13,528 option-related shares and several large sales by Maetzold and the Maetzold Descendants 2020 Trust.
Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF Value Says Undervalued
Castle Biosciences Inc (CSTL) shares recently dropped 3.0%, leading to a 7.5% decrease over the past week, but GuruFocus' GF Value indicates the stock is slightly undervalued. Despite a strong GF Score of 81/100, driven by high growth potential, the company faces significant challenges with profitability (rated 4/10) as it is currently unprofitable. Insider selling of $4.2 million over the last three months, with no insider buying, suggests a mixed sentiment from institutional investors and a cautious outlook from insiders.
CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ
A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted stock acquired from the issuer on various dates in 2025 and 2026. This planned sale represents a small fraction of the total 30,549,507 shares outstanding.
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Castle Biosciences (NASDAQ: CSTL) raised its full-year outlook after exceeding second-quarter expectations, primarily driven by strong performance from its DecisionDx-Melanoma and TissueCypher tests, along with increased physician adoption. The DecisionDx-Melanoma test continues to be a key growth driver, showing mid- to high-single-digit volume growth, while TissueCypher for Barrett's esophagus patients still has significant penetration opportunity. The company expects to remain adjusted-EBITDA positive through 2026 and 2027, despite the newer AdvanceAD-Tx test for atopic dermatitis not contributing significantly to revenue until 2027 due to ongoing reimbursement efforts.
Wasatch Advisors LP Sells 175,687 Shares of Castle Biosciences, Inc. $CSTL
Wasatch Advisors LP significantly reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by selling 175,687 shares, representing a 38.6% decrease, and now holds 279,349 shares valued at approximately $6.66 million. Despite this reduction by Wasatch Advisors, institutional investors collectively own 92.6% of CSTL. The company recently reported better-than-expected quarterly earnings, with a loss of $0.07 per share against an estimated $0.41 loss, and revenues of $99.86 million surpassing expectations of $86.23 million.
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Castle Biosciences (NASDAQ: CSTL) raised its full-year outlook after its second-quarter performance surpassed expectations, driven by strong adoption and modest pricing gains for its DecisionDx-Melanoma and TissueCypher tests. While DecisionDx-Melanoma is a core growth engine with significant market penetration, TissueCypher has substantial room for expansion. The company anticipates remaining adjusted-EBITDA positive through 2026 and 2027, with potential future revenue from its AdvanceAD-Tx test for atopic dermatitis.
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 2,546 Shares
Castle Biosciences insider Derek Maetzold sold 2,546 shares of the company's stock for approximately $78,111, reducing his position by 10.6%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently surpassed quarterly revenue and EPS expectations, and while analyst sentiment is generally positive, several insiders have sold shares, though these sales were pre-planned.
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 20,356 Shares of Stock
Castle Biosciences insider Derek Maetzold sold 20,356 shares of the company's stock for over $633,000, reducing his ownership by nearly half. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently reported better-than-expected quarterly results, and analysts maintain a "Moderate Buy" rating with a consensus price target of $42.00.
Tobin Juvenal Sells 1,301 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
Tobin Juvenal, an insider at Castle Biosciences (NASDAQ:CSTL), sold 1,301 shares of the company's stock for approximately $49,945, reducing his position by 1.65%. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Despite insider sales, Castle Biosciences' recent quarterly results exceeded expectations with higher revenue and a narrower per-share loss, and Wall Street maintains a "Moderate Buy" consensus with an average price target of $42.00.
Dimensional Fund Advisors LP Sells 104,038 Shares of Castle Biosciences, Inc. $CSTL
Dimensional Fund Advisors LP reduced its stake in Castle Biosciences (NASDAQ:CSTL) by 9.1%, selling 104,038 shares but still retaining over 1 million shares valued at approximately $25.5 million. This comes as Castle Biosciences exceeded Q1 revenue and EPS expectations, reporting $99.86 million in revenue and a $0.07 per-share loss. Despite some recent insider sales, analysts maintain a "Moderate Buy" consensus with an average price target of $42.
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 19,040 Shares
Tobin Juvenal, Chief Commercial Officer of Castle Biosciences (CSTL), sold 19,040 shares of the company's stock for approximately $556,158. This transaction is part of a broader trend of insider selling at Castle Biosciences, with 50 insider sells and zero buys over the past year. Despite the insider selling, GuruFocus's valuation model suggests the stock is "Fairly Valued" at a price-to-GF-Value ratio of 0.99, and some institutional investors are adding to their positions, indicating a divergent opinion on the company's prospects.
BTIG raises Castle Biosciences stock price target on strong revenue
BTIG has increased its price target for Castle Biosciences (CSTL) to $44 from $40, maintaining a Buy rating, citing the company's strong 20% revenue beat and 20% growth. This performance was primarily driven by the TissueCypher franchise, with significant volume increases. Despite the stock trading below its 52-week high, BTIG sees a large market opportunity in atopic dermatitis that is not yet reflected in the share price, and InvestingPro analysis suggests the stock is currently slightly overvalued relative to its fair value.
CFO Awards honoree Frank Stokes of Castle Biosciences Inc.
Frank Stokes of Castle Biosciences Inc. has been recognized as an honoree for the Houston Business Journal's 2026 CFO Awards. The article highlights Stokes as one of several distinguished individuals acknowledged for their financial leadership. Other honorees include Frank Wilson IV, Ebru Akyildiz, Stephanie Alvarez, and Chinelo Aralu.
Castle Biosciences Q2 Earnings Call Highlights
Castle Biosciences reported strong second-quarter 2026 results, with revenue up 20% to $103.5 million, driven by the growth of its TissueCypher test and other core offerings. The company raised its full-year revenue outlook to $365-$375 million and anticipates positive adjusted EBITDA for the remainder of 2026 and all of 2027. Growth was attributed to strategic investments in commercial resources, clinical evidence, and pipeline programs, alongside increasing test volumes for TissueCypher and modest gains in DecisionDx-Melanoma.
Castle Biosciences 2026: Revenue $103.55M, EPS ($0.07) — 10-Q Summary
Castle Biosciences (CSTL) reported its 2026 financial results, showing revenue of $103.55 million, an increase from $86.19 million in the previous year. However, the company posted a net loss of ($2.06 million) and diluted EPS of ($0.07), a decline from the prior year's net income of $4.52 million and EPS of $0.15. Revenue growth was primarily driven by the expansion into non-dermatologic tests, with TissueCypher volumes significantly increasing, and early interest in the AdvanceAD-Tx launch.
Castle Biosciences, Inc. Stock 12‑Month Price Target Raised to $43.56, Implies 63% Upside
Castle Biosciences, Inc. (CSTL) has seen its average 12-month price target raised to $43.56 from $42.78 by 9 analysts, implying a potential upside of approximately 63% from its July 30 closing price. The consensus rating for the stock remains a "Buy" across all covering analysts.
CSTL (CSTL) insider schedules potential $630,000 sale of 22,500 shares
An affiliate of CASTLE BIOSCIENCES INC (CSTL) has filed a Form 144 to sell 22,500 shares of common stock, with an aggregate market value of $630,000. The shares, originating from various equity compensation grants including Restricted Stock Units and Restricted Stock Awards, are scheduled for potential sale through a broker-dealer on or after July 31, 2026. The filing provides details on the acquisition dates and sizes of these compensation grants, with the largest individual grant being 12,074 Restricted Stock Units acquired on December 9, 2024.
Form 144 Castle Biosciences For: 1 August By Investing.com
This article announces the filing of Form 144 for Castle Biosciences (CSTL) on August 1st. It provides a brief mention of the company's stock performance, showing a 4.52% increase. The content largely consists of market data, trending stocks, and various financial tools provided by Investing.com, rather than in-depth analysis of the Form 144 itself.
Castle Biosciences (CSTL) Stock Climbs On Higher Sales Outlook Despite Margin Pressure
Castle Biosciences (CSTL) stock saw a 4.5% jump after its Q2 earnings report, driven by a 20% revenue increase to US$103.5m and an uplifted full-year sales guidance, despite reporting a small net loss. The market appears to be prioritizing the strong top-line growth and positive outlook over the short-term margin pressure and net loss. The company's growth is fueled by increased volumes in its diagnostic tests and progress in reimbursement milestones for new products, while challenges remain in gross margin decline and operating expense increases.
Key facts: CSTL Q2 Revenue $103.6M; AdvanceAD-Tx 97.8% Concordance
Castle Biosciences (CSTL) reported Q2 revenue of $103.55 million, exceeding estimates of $86.2 million, despite an operating loss of $3.07 million. Additionally, a study revealed that the company's AdvanceAD-Tx testing for atopic dermatitis showed a 97.8% concordance in systemic therapy decisions, significantly higher than the 54.3% baseline.
Castle Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CSTL)
Castle Biosciences, Inc. released its Q2 2026 earnings call presentation. The company reported an EPS of -$0.07, beating estimates by $0.34, and revenue of $103.55M, an increase of 20.14% year-over-year, beating estimates by $17.30M. This report accompanies their earnings call from July 31, 2026.
Earnings call transcript: Castle Biosciences tops Q2 2026 estimates, shares jump
Castle Biosciences (CSTL) exceeded second-quarter 2026 profit and revenue estimates, leading to a significant jump in its share price and an increase in full-year sales guidance. The company reported an adjusted loss of 7 cents per share on revenue of $103.5 million, outperforming analyst expectations. Growth was primarily driven by strong demand for its DecisionDx-Melanoma and TissueCypher tests, with a notable organic revenue increase of 40% excluding legacy products.
Earnings Flash (CSTL) Castle Biosciences Posts Q2 Adjusted EPS -$0.07, vs. FactSet Est of -$0.41
Castle Biosciences (CSTL) reported Q2 adjusted EPS of -$0.07, significantly outperforming FactSet's estimate of -$0.41. The company also posted Q2 revenue of $103.5 Million, surpassing the FactSet estimate of $86.2 Million. This positive earnings flash comes alongside other recent company news, including Health Department approvals for its AdvanceAD-Tx test and publication of a study on its DecisionDx-Melanoma test.
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) reported a Q2 loss of $0.07 per share, significantly beating the Zacks Consensus Estimate loss of $0.44 due to non-recurring items. The company also surpassed revenue estimates with $103.55 million, an 18.61% beat, continuing a trend of outperforming revenue expectations over the last four quarters. Despite these positive surprises, the stock has underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #3 (Hold).
Form 4 Castle Biosciences Inc For: 29 July By Investing.com
This article by Investing.com is a brief notice about a Form 4 filing for Castle Biosciences Inc. on July 29. It provides minimal information, mainly serving as an announcement of the filing regarding the company (CSTL).
Castle Biosciences CEO Maetzold sells $237,682 in company stock
Castle Biosciences CEO Derek J. Maetzold sold $237,682 worth of company stock through direct sales and various trusts on July 27, 2026, under a Rule 10b5-1 trading plan. Despite the sales, Maetzold also acquired 6,214 shares by exercising vested stock options. The company is set to report earnings soon, with analysts maintaining a bullish outlook, amidst recent positive developments like exceeding revenue expectations and securing new test approvals.
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $150,130.24 in Stock
Castle Biosciences (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the company's stock, totaling $150,130.24, under a pre-arranged Rule 10b5-1 plan. This transaction reduced his ownership by 22.44%. The company's stock was trading up 2.4% at $24.46, and analysts maintain a "Moderate Buy" consensus rating with an average target price of $42.43.
Castle Biosciences Inc (CSTL) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Castle Biosciences Inc (CSTL), noting its current valuation score of 8.65, which ranks it 75th in the Healthcare Equipment & Supplies industry. The P/E ratio stands at -58.82, significantly below its recent high and above its recent low. However, key financial metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts
Castle Biosciences, Inc. (NASDAQ:CSTL) has received an average "Moderate Buy" recommendation from analysts, with a 12-month target price of $42.43. While the company met EPS expectations at -$0.49 and exceeded revenue estimates with $84.23 million, it remains unprofitable. Insider activity shows recent sales of shares by Derek J. Maetzold and Kristen M. Oelschlager, totaling approximately $1.01 million over the last 90 days.
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Castle Biosciences Inc's (CSTL) financial health, noting its current score of 7.55 and ranking within the Healthcare Equipment & Supplies industry. It highlights the company's robust financial status but average operating efficiency. The report also details recent quarterly revenue and net profit changes, both showing year-over-year decreases.
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk
Castle Biosciences Inc (CSTL) has a current risk assessment score of 7.04, placing it 44th out of 200 in the Healthcare Equipment & Supplies industry. The company's beta of 1.07 indicates higher volatility compared to the S&P 500. The article details various risk metrics including maximum drawdown, volatility, Sharpe Ratio, and liquidity.
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Castle Biosciences Inc (CSTL). It indicates that detailed data for business segments, regional revenue, and profit contribution for various fiscal years are not yet disclosed by the company. The only specific financial detail available is the United States regional revenue of $344.23 million, with a 0.00% proportion.
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Castle Biosciences Inc (CSTL), listing major institutional holders and their respective proportions. It also presents a breakdown of shareholder types by category, showcasing the significant influence of investment advisors and hedge funds. Furthermore, the report includes institutional shareholding trends over several quarters and recent shareholder activity with changes in holdings for key investors.
Castle Biosciences (CSTL) Expected to Post Quarterly Earnings on Thursday
Castle Biosciences (CSTL) is scheduled to release its Q2 2026 earnings on Thursday, July 30th, with analysts forecasting a loss of $0.44 per share on $86.24 million in revenue. The company's previous quarter exceeded revenue expectations, reporting $84.23 million against estimates of $79.23 million. Analyst sentiment for CSTL remains a "Moderate Buy," with a consensus target price of $42.43, despite some recent rating cuts and lowered price targets from various firms.
Castle Biosciences sets live webcast for Aug. 12 conference
Castle Biosciences (Nasdaq: CSTL) announced that its executive management will present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 11:30 a.m. Eastern time. A live audio webcast and replay will be available on the company's investor relations events webpage. The company develops innovative diagnostic tests, primarily focusing on dermatologic and gastroenterological diseases.
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Castle Biosciences, Inc. (Nasdaq: CSTL) will present a company overview at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 11:30 a.m. Eastern time. A live audio webcast will be available on the Company's investor relations website, with a replay accessible afterward. Castle Biosciences focuses on innovative diagnostic tests for dermatologic and gastroenterological diseases.
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Castle Biosciences, Inc. (Nasdaq: CSTL) announced its executive management will present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 11:30 a.m. Eastern time. A live audio webcast will be available on the company's website, with a replay accessible after the broadcast. Castle Biosciences focuses on improving health through innovative tests in dermatologic and gastroenterological diseases.
New York State Department of Health Approves Castle’s AdvanceAD-Tx Test
The New York State Department of Health has approved Castle Biosciences, Inc.'s AdvanceAD-Tx test, a non-invasive gene expression profile test for guiding systemic therapy selection in moderate-to-severe atopic dermatitis patients. This approval broadens access to the test in New York, which helps clinicians personalize treatment based on a patient's individual disease biology, potentially leading to faster symptom relief. Castle Biosciences now holds New York State approval for all tests in its dermatology and ophthalmology portfolios, as well as its TissueCypher test in gastroenterology.
Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts
Castle Biosciences Inc. President and CEO Derek J. Maetzold reported selling 4,172 shares of common stock at a weighted-average price of $22.92 per share on July 14, 2026. These sales were largely executed through family trusts under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Maetzold also exercised stock options for 550 shares at $2.39 per share.
